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Abstract
Loss of muscle mass and force with age leads to fall risk, mobility impairment, and reduced quality of life. This article shows that BDA-410, a calpain 
inhibitor, induced loss of body weight and fat but not lean mass or skeletal muscle proteins in a cohort of sedentary 23-month-old mice. Food and 
water intake and locomotor activity were not modified, whereas BDA-410 treatment decreased intramyocellular lipid and perigonadal fat, increased 
serum nonesterified fatty acids, and upregulated the genes mediating lipolysis and oxidation, lean phenotype, muscle contraction, muscle transcription 
regulation, and oxidative stress response. This finding is consistent with our recent report that lipid accumulation in skeletal myofibers is significantly 
correlated with slower fiber-contraction kinetics and diminished power in obese older adult mice. A proteomic analysis and immunoblot showed 
downregulation of the phosphatase PPP1R12B, which increases phosphorylated myosin half-life and modulates the calcium sensitivity of the contractile 
apparatus. This study demonstrates that BDA-410 exerts a beneficial effect on skeletal muscle contractility through new, alternative mechanisms, 
including enhanced lipolysis, upregulation of “lean phenotype-related genes,” downregulation of the PP1R12B phosphatase, and enhanced excitation–
contraction coupling. This single compound holds promise for treating age-dependent decline in muscle composition and strength.
Keywords: Skeletal muscle—Aging—Calpain—Body fat—Sarcopenia
Skeletal muscle plays a role in systemic aging and constitutes an 
independent determinant of life span (1). Loss of muscle mass and 
force with age, termed sarcopenia, leads to fall risk, mobility impair-
ment, and reduced quality of life (2). We discovered that decreased 
expression of the voltage-gated calcium channel α1 subunit (Cav1.1) 
accounts for excitation–contraction uncoupling and force decline 
with aging (3–5). We also reported that increased expression of 
Cavβ1a subunit contributes to skeletal muscle weakness by decreas-
ing levels of Cav1.1 protein without interfering with transcription of 
its encoding gene, Cacna1s (6). These and other mechanisms underly-
ing skeletal muscle impairment with aging have been reviewed (7,8).
Recently, we reported that troponin T3 (TnT3) regulates Cacna1s 
transcription and Cav1.1 expression by binding a consensus sequence 
at the Cacna1s promoter region. Furthermore, endogenous cleavage 
of TnT3 accounts for decreased Cav1.1 expression with aging (9,10). 
Detailed analysis of the TnT3-Cacna1s interaction showed that the 
TnT3 endogenous cleavage site in muscle in vivo is compatible with 
calpain activity, and BDA-410, a synthetic cyclopropenone deriva-
tive that specifically and reversibly inhibits cysteine proteases such 
as calpains (11), stabilizes nuclear TnT3 integrity in skeletal muscle 
from old mice in vivo. We also found that calpain inhibition does not 
modify overall levels of the main motor and regulatory proteins or 
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fiber type in fast and slow muscles from old mice. We discovered that 
inhibiting calpain by oral BDA-410 administration rescued Cav1.1 
protein levels in old sedentary mice and enhanced muscle excitation–
contraction coupling and force generation in old mice (9,10,12).
Here, we report that, compared to control vehicle-treated mice, 
BDA-410-treated mice experienced significant decrease in body weight. 
Because changes in body weight occurred in a cohort of mice that 
exhibited improved skeletal muscle force, we examined whether BDA-
410 activates metabolic pathways involved in protein and/or lipid 
metabolism and their potential to increase muscle function. Because 
most relevant proteins involved in force generation did not change 
with BDA-410 treatment (10), we hypothesized that loss in body fat 
accounts for the observed loss in body weight and enhanced muscle 
force. White adipose tissue (WAT) is involved in pathways regulating 
life span, age-related diseases, inflammation, and metabolic dysfunc-
tion, and its removal from visceral depots enhances insulin sensitivity 
and extends life span in laboratory rodents (13). Because we reported 
that lipid accumulation in skeletal myofibers significantly correlates 
with slower fiber-contraction kinetics and diminished power in obese 
older adults (14), we propose that BDA-410-induced fat loss contrib-
utes to enhanced force generation in sedentary senescent mice.
This study shows that BDA-410 may exert a beneficial effect on 
skeletal muscle contractility through new, alternative mechanisms to 
those recently proposed (10), including enhanced lipolysis, upregulation 
of “lean phenotype-related genes,” and downregulation of the PP1R12B 
phosphatase, which increases phosphorylated myosin half-life and 
modulates calcium sensitivity of the contractile apparatus. A single com-
pound that combines all these major positive effects has great potential 
in treating age-dependent decline in muscle composition and strength.
Materials and Methods
Animals
Twenty-three-month-old female C57BL/6 mice from the Charles 
River-NIA colony were used for this and our previous report (10). 
They were housed in a pathogen-free area at Wake Forest School of 
Medicine (WFSM), four per cage, at 20–23°C, with a 12:12-h dark–
light cycle, and ad-libitum access to food and water. Mouse handling 
and procedures followed a protocol approved by the WFSM Animal 
Care and Use Committee.
BDA-410 Administration Protocol
The calpain inhibitor BDA-410, (2S)-N-(1S)-1-[(S)-hydroxy(3-oxo-
2-phenyl-1-cyclopropen-1-yl)methyl]-2-methylpropyl-2-benzenesul-
fonylamino-4-methylpentanamide, is a cyclopropenone derivative, 
synthesized and kindly provided by Mitsubishi Tanabe Pharma 
Corporation (Yokohama, Japan). Two groups of 23-month-old mice 
received either 1% Tween 80 in normal saline (vehicle) or BDA-410 
dissolved in vehicle at 30 mg/kg/d by gavage for 21 consecutive days. 
This dose and administration route are reported to lead to a 24 nM 
plasma concentration and a maximum concentration after per os 
bolus of ~12 ng/mL (15).
Statistical Analysis
Data were analyzed using SigmaPlot 12.5 (Systat Software, San José, 
CA) or Prism 6.0a (GraphPad Software, La Jolla, CA). All data are 
expressed as means ± SEM, and reported p values are the result of 
two-sided tests. The alpha level was set at p < .05. Student’s t-test 
or analysis of variance was used to compare experimental groups 
where appropriate.
See Supplementary Methods for a detailed description of skeletal 
muscle collection, measurements of body weight, body composition, 
food and water intake, spontaneous locomotor activity, microarray 
data processing and statistical analysis, real-time PCR mRNA analy-
sis, nanoscale liquid chromatography to tandem mass spectrometry, 
label-free protein quantification using precursor integrity, intramyo-
cellular lipid (IMCL), fiber type and nonesterified fatty acids assay, 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and 
immunoblotting for PP1R12B phosphatase.
Results
BDA-410 Induced Loss in Body Weight and Fat Content
We treated two groups of 23-month-old female C57BL/6 mice with either 
1% Tween 80 dissolved in saline (vehicle group) or 30 mg/kg/d BDA-410 
dissolved in vehicle (BDA-410 group) by gavage for 21 consecutive days. 
At baseline, mice weight did not differ between groups (Figure 1A), but 
the percent change in body weight between posttreatment and pretreat-
ment was statistically significant (Figure 1B; p = .01), because the vehicle-
treated group increased, whereas the BDA-410-treated group decreased. 
To determine whether changes in body composition account for body 
weight loss with BDA-410 treatment, we measured body fat and lean 
mass by dual-energy X-ray absorptiometry scanning (Figure  1C). 
Although the BDA-410 group lost a significant amount (~16%) of body 
fat, the vehicle-treated mice gained ~8% (p = .042). Lean mass (in grams) 
did not differ between BDA-410- (pre: 20.0 ± 0.44, post: 21.2 ± 0.42; 
p = .1) and vehicle-treated (pre: 20.8 ± 0.43, post: 20.6 ± 0.48; p = .365) 
mice. Figure 1D illustrates dual-energy X-ray absorptiometry scans of 
a mouse before and after BDA-410 treatment. These results indicate 
that BDA-410 induces body weight loss by reducing fat content without 
altering muscle mass (10). We also recorded the weight of perigonadal 
WAT (Figure 1E), lung, heart, spleen, kidney, and liver (Figure 1G). The 
loss in fat content is statistically significant only in perigonadal WAT 
and soleus muscle. Histological measures of lipid droplets (total lipid 
droplet area, number of lipid droplets, average of each droplet area, and 
area fraction) in the soleus muscle from BDA-410- and vehicle-treated 
mice show that, compared to vehicle, BDA-410 significantly decreases 
IMCL content in both type-1 and type-II fibers (Figure 1F and Table 1). 
The significant increase of serum nonesterified fatty acids concentration 
in BDA-410-treated mice compared to vehicle-treated mice (Figure 1G) 
further supports the conclusion that BDA-410 enhances lipolysis in sed-
entary senescent mice.
BDA-410 Administration Does Not Modify Food and 
Water Intake
We also examined whether reductions in calorie or water intake con-
tributed to loss of body fat content or body weight, respectively. Daily 
food and water intake were recorded for each mouse for 3 consecutive 
days before and after BDA-410 or vehicle administration and normal-
ized to body weight recorded the same day. Figure 2 shows that BDA-
410- and vehicle-treated mice did not differ in absolute (Figure 2A) 
or normalized-to-body-weight (Figure 2B) food intake and absolute 
(Figure 2C) or normalized (Figure 2D) water intake. These data indi-
cate that BDA-410 does not alter food or water intake suggesting that 
changes in body weight and fat were independent of caloric intake.
BDA-410 Does Not Modify Spontaneous Locomotor 
Activity
As physical activity may result in body weight loss through increased 
energy expenditure, we examined whether BDA-410 induced 
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increased mouse activity compared to baseline and the control group. 
Mice were placed on an open field arena, and their spontaneous 
activity was recorded continuously for 2–5 minutes in the absence or 
presence of an object using a computerized tracking system. We com-
puted time spent moving in the empty field (Figure 3A), total distance 
traveled (Figure  3C), average speed (Figure  3E), and spontaneous 
maximal speed (Figure 3G) over 3 consecutive days before and imme-
diately after BDA-410 or vehicle treatment. The same parameters were 
recorded in the presence of an object (Figure 3B, D, and F). Although 
overall mobility and total travel time tended to be lower in the BDA-
410-treated mice than the control, the difference was not statistically 
significant. Because BDA-410 did not increase spontaneous locomo-
tion, it must induce the leaner phenotype by another mechanism.
BDA-410 Treatment Reduces IMCL
IMCL data were obtained in 6 mice (3 BDA-410 and 3 vehicle 
treated), and a total of 335 soleus fibers (160 BDA-410, 175 vehicle) 
were identified by their lipid droplet characteristics and fiber type, 
determined by Oil-red-O (Figure 1F) and ATP-ase staining (14). As 
shown in Table 1, type-I fibers had greater total lipid droplet area 
and more lipid droplets (p < .01) than type-II fibers in both groups, 
but this difference was more pronounced in the vehicle group. 
Additionally, total lipid droplet area, number of lipid droplets, 
average of each droplet area, and area fraction were about twofold 
greater in both type-I and type-II fibers from the vehicle group com-
pared to the BDA-410 group (p < .01). In summary, fibers from the 
vehicle group showed about a twofold greater area of lipid droplet 
than fibers from the BDA-410 group, especially in the type-I fibers.
Genes Encoding Mediators of Lipolysis and Fat 
Oxidation are Upregulated in the Skeletal Muscle of 
BDA-410-Treated Mice
To understand the mechanism underlying the loss in body weight 
and fat recorded in BDA-410-treated mice, we examined the gas-
trocnemius muscle’s transcriptome using RNA microarrays in 
mice treated with BDA-410 or vehicle. The statistical analysis 
revealed 2,559 differentially expressed transcripts with −2.05- to 
9.85-fold change (p < .05); specifically, 1,241 genes were upregu-
lated (1.02- to 9.84-fold change), whereas 1,318 were downreg-
ulated (−1.02- to −2.05-fold change). A  volcano plot shows the 
general distribution of these transcripts according to statistical 
significance (y-axis, p value) and fold change (x-axis, means dif-
ference; Figure 4A). Gene ontology annotation of 106 genes with 
a change larger than 1.5-fold revealed major clustering around the 
following biological processes: lipid metabolism, the peroxisome 
proliferator-activated receptor (PPAR)-adiponectin pathway, the 
insulin-like growth factor 1 pathway, response to oxidative stress, 
and cell aging (Figure 4B).
Figure  1. BDA-410 treatment induced loss of weight and body fat but not 
lean mass in mice. Baseline (A) and change (B) in mouse body (n = 8 vehicle, 
n = 9 BDA-410; *p =  .01). (C) Change in body fat measured by dual-energy 
X-ray absorptiometry scans (n  =  8 vehicle, n  =  9 BDA-410; *p  =  .042). (D) 
Representative dual-energy X-ray absorptiometry scans of a BDA-410-treated 
mouse that lost 28% of its body fat. Dotted lines denote the thickness of 
subcutaneous WAT in the flank (n = 4). (E) Perigonadal fat weight in BDA-
410- (n = 5) and vehicle-treated mice (p < .05). (F) Oil-red-O staining of soleus 
muscle from BDA-410- and vehicle-treated mice. (G) Lung, heart, spleen, 
kidney, liver, and soleus muscle weight and serum nonesterified fatty acids 
concentration in BDA-410- (n = 5) and vehicle-treated (n = 5) mice.
Table 1. Intramyocellular lipids in BDA-410- and vehicle-treated mice
BDA-410 Vehicle
Type I (102 fibers) Type II (58 fibers) Type I (108 fibers) Type II (67 fibers)
Droplet area (µm2) 198 ± 9.4a 72 ± 5.8 357 ± 28a,b 130 ± 5.9b
Number of lipid droplets 124 ± 4.5a 48 ± 3.1 214 ± 9a,b 88 ± 5.6b
Average of each droplet area (µm2) 1.3 ± 0.05 1.1 ± 0.05 1.5 ± 0.04a,b 1.4 ± 0.07b
Area fraction (%) 6.1 ± 0.32a 2.7 ± 0.09 9.1 ± 0.17a,b 4.6 ± 0.45b
Data are mean ± SEM.
Total number of muscle fibers analyzed: 335.
aSignificantly different than type-II fiber type within group treatment.
bSignificantly different than corresponding fiber type of BDA-410 group.
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To define the molecular pathways modified by BDA-410, we 
searched for relevant genes among those differentially expressed. 
Supplementary Table  1 lists selected transcripts, and a heat map 
represents the expression level of each sample for both mouse 
groups (Figure 4C). We confirmed upregulation of Adipoq, Dgat1, 
Angptl4, Fabp4, and Ppard gene transcripts by qPCR. Values for 
relative expression post- and pre-BDA-410 treatment were 8.4 ± 1.7, 
1.9 ± 0.23, 4.1 ± 0.62, 3.2 ± 0.46, and 1.5 ± 0.33, respectively.
Figure  4D shows the functional connections between these 24 
differentially expressed genes in (Figure  4C) using the STRING10 
database. The most significantly upregulated genes were Adipoq, 
Angptl4, Fabp4, Retnla, Dgat1, Acsl3, Cdh13, and Ppard (see 
Supplementary Table  1 and Figure  5), which codify for adiponec-
tin (ADIPOQ), angiopoietin-like 4 (ANGPTL4), fatty acid binding 
protein 4 (FABP4), resistin-like alpha (RETNLA), diacylglycerol 
O-acyltransferase 1 (DGAT1), acyl-CoA synthetase long-chain family 
member 3, T-cadherin, and peroxisome proliferator-activated recep-
tor delta (PPARδ) proteins, respectively. In contrast, known negative 
modulators of metabolic pathways such as Nrip1 (nuclear receptor 
interacting protein 1 or RIP140) and Ppargc1b (peroxisome prolifer-
ator-activated receptor-γ coactivator-1β [PGC-1β]) were downregu-
lated, contributing to increased transcription of the Ppard gene and 
its downstream effectors, such as ANGPTL4, which activate lipolysis.
Apart from voluntary physical activity, skeletal muscle metabolism 
and endocrine function have a significant impact on whole-body met-
abolic homeostasis by producing and secreting molecules with parac-
rine and endocrine function, termed myokines. In BDA-410 treated 
mice, mRNA was upregulated for five myokine genes: Adipoq (+9.85-
fold change; p = .023), Ifi27l2a (+3.20-fold change; p = .045), Angptl4 
(+2.59-fold change; p = .007), Fabp4 (+2.46-fold change; p = .016), 
and Retnla (+2.25-fold change; p  =  .021; Supplementary Table  1). 
These genes may mediate body fat loss in BDA-treated mice by stimu-
lating muscle-derived lipolysis and inhibiting adipocyte differentiation 
(see the following sections). Note that Adipoq, Ucp3 (mitochondrial 
uncoupling protein 3; +1.28-fold change; p = .040), Dgat1 (+1.45-fold 
change; p = .041), and Ppard, which are significantly upregulated in 
the skeletal muscle of BDA-410-treated mice (Supplementary Table 1), 
are directly associated with a lean phenotype.
BDA-410 Upregulates Genes Associated With 
Muscle Contraction Regulation, Calcium 
Homeostasis, Excitation–Contraction Coupling, and 
Actin Filament Dynamics
BDA-410 increased expression of genes involved in (a) skeletal mus-
cle structure and function, including Igf1 (insulin-like growth factor 
1; +1.70-fold change; p = .034), Igfbp3 (insulin-like growth factor 1 
binding protein 3; +1.94-fold change; p = .010), and Igfbp4 (insulin-
like growth factor 1 binding protein 4; +1.95-fold change; p = .023); 
(b) intracellular calcium homeostasis and excitation-contraction 
coupling: Camk2d (calcium/calmodulin-dependent protein kinase II 
delta; +1.46-fold change; p  =  .018), Csrp3 (cysteine- and glycine-
rich protein 3/muscle LIM protein; +2.50-fold change; p  =  .038), 
and Dnm2 (dynamin-2; −1.07-fold change; p = .038); and (c) actin 
filament dynamics: Gsn (gelsolin; +1.53-fold change; p  =  .034; 
Supplementary Table 1).
BDA-410 Induces Overexpression of Genes 
Associated With Transcription Regulation
Gene expression involves finely tuned regulation by factors that modu-
late the timing and frequency of DNA transcription. In mice, BDA-410 
Figure 2. BDA-410 did not modify food and water intake. Daily food (A) and 
water (B) intake recorded for each mouse 3 consecutive days before and after 
treatment and normalized to mouse weight (C and D) (n = 5 mice for BDA-
410-treated mice and n = 4 mice for the vehicle-treated group).
Figure  3. BDA-410 did not modify spontaneous locomotor activity. Mouse 
mobility tested in an open field arena in the absence (A, C, E, G) or presence 
(B, D, F) of an object. Mice treated with BDA-410 (n = 5) or vehicle (n = 4) were 
examined for time spent in motion (A and B); percent of the trial spent moving 
(C); total traveled distance (D); average speed (E and F); and spontaneous 
maximal speed (G).
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increases a group of transcription factors generically known as mediator 
complex (MED), including Med4, Med9, Med20, and Med31. The tran-
scription factor Nr2c2 (nuclear receptor subfamily 2, group C, member 
2) is also upregulated, whereas Med13, Med29, Nrip1, and Ppargc1b are 
downregulated compared to skeletal muscle from vehicle-treated mice 
(Supplementary Table 1). These transcription factors have been reported 
to regulate Ppard, Angptl4, and Adipoq gene expression (Figure 5).
BDA-410 Upregulates Genes Associated With 
Oxidative Stress Response
By ontology analysis, we found that transcripts related to oxida-
tive stress response form a cluster in BDA-410-treated compared to 
vehicle-treated mice. Upregulated genes in this cluster include: Gpx3 
(glutathione peroxidase 3), Serping1 (serine [or cysteine] peptidase 
inhibitor, clade G, member 1), Gpx1 (glutathione peroxidase 1), 
Figure 4. Effects of BDA-410 on skeletal muscle gene expression. (A) Volcano plot representing differentially expressed genes in the gastrocnemius muscle of 
BDA-410- and vehicle-treated mice. Dots represent gene transcripts. The red dots represent those that displayed high statistical significance (y-axis; p < .05). 
The x-axis shows the mean difference between the BDA-410 (n = 4) and control (n = 4) groups; it measures the magnitude of change in expression levels. (B) 
Gene ontology (GO) classification. Scatterplot of significant biological pathways (p < .05), including genes showing over a 1.5-fold change with treatment. (C) 
Supervised clustering analysis of differentially expressed genes. The heat map shows differential expression of 24 selected genes in the skeletal muscle from 
BDA-410- and vehicle-treated mice. Fold change values are in Supplementary Table 1. (D) Protein–protein interactions among the 24 selected, differentially 
expressed genes. Thicker lines represent stronger associations.
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Sod3 (superoxide dismutase 3), and Prdx2 (peroxiredoxin 2; 
Supplementary Table 1).
BDA-410 Treatment Downregulates PPP1R12B 
Muscle Phosphatase
Because calpains have many intracellular targets, we analyzed the 
protein expression profile of whole protein extractions from soleus 
muscle of BDA-410- and vehicle-treated mice (n = 3 muscles from 
3 mice per group) by nanoscale liquid chromatography coupled 
to tandem mass spectrometry. Data analysis showed significant 
differences between groups for proteins with few known connec-
tions with the previously discussed pathways, except for protein 
phosphatase 1 regulatory subunit 12B (PPP1R12B; protein 47 in 
Supplementary Table 2), which plays a crucial role in muscle force 
development by modulating the calcium sensitivity of the contrac-
tile apparatus. We confirmed by immunoblot that PPP1R12B was 
downregulated in the BDA-410 compared to the vehicle group 
(Figure 6A and B).
Discussion
The morbidity and mortality rates of several aging-related diseases 
correlate with functional capacity, metabolic demand, and muscle 
mass, and skeletal muscle metabolic status as well as body weight 
and composition influence muscle contraction efficiency (16–18). 
The work reported here shows that BDA-410, a known calpain 
inhibitor, induces loss of body weight and fat but not lean mass or 
skeletal muscle proteins in sedentary senescent female mice inde-
pendently of food and water intake and spontaneous locomotor 
activity. BDA-410 treatment upregulated genes mediating lipolysis 
and fat oxidation, lean phenotype, muscle contraction, muscle tran-
scriptional regulation, and oxidative stress responses. In addition, an 
unbiased protein screening and immunoblot analysis showed down-
regulation of the phosphatase PPP1R12B.
Body Weight, Body Composition, and Lipolysis
Our data indicate that systemic administration of BDA-410 to old 
C57BL/6 mice evokes differential expression of many genes involved 
in lipid metabolism, energy homeostasis, and muscle-adipose tissue 
crosstalk. BDA-410 significantly induced transcription of key mus-
cle-derived metabolic modulator genes, such as Angptl4, Adipoq, 
Ppard, and Retnla, as well as their cellular receptors and downstream 
effectors. These molecules are responsible for promoting lipolysis, 
blocking adipogenesis, and increasing fatty acid uptake and oxida-
tion by peripheral tissues (19,20). Figure 5 shows a scheme of these 
pathways and their interaction. The Ppard gene encodes PPARδ, the 
main isoform in skeletal muscle. PPARδ is thought to be a key coor-
dinator of fatty acid oxidation and energy uncoupling in both adi-
pocytes and myocytes (21), and it controls fatty acid transport into 
the muscle, beta-oxidation, and mitochondrial respiration (22,23). 
Specific overexpression of PPARδ in mouse skeletal muscle increased 
FABP3 and uncoupling proteins (UCP) expression and reduced body 
fat content by decreasing the size of adipose cells (24).
Here, we show that BDA-410 downregulates the Nrip1 and 
Ppargc1b genes, thus contributing to increased Ppard expression. 
It differentially regulates several members of the mediator complex, 
upregulating Med9, Med20, Med4, and Med31 and downregulating 
Med29 and Med13 compared to control. PPARδ positively regulates 
the Angptl4 gene, which codifies for angiopoietin-like 4 protein, 
which the skeletal muscle secretes into the blood stream, where it acts 
as a myokine, modulating adiposity by inhibiting lipoprotein-lipase 
and enhancing intracellular lipolysis in WAT (25). Additionally, cir-
culating levels of ANGPTL4 negatively correlate with body weight 
and body fat content with no changes in calorie intake or physical 
activity (26). During increased lipolysis, circulating free fatty acids 
(FFAs) stimulate skeletal muscle to synthesize and secrete fatty acid 
Figure  5. Schematic representation of differentially expressed genes 
in the skeletal muscle of old, sedentary C57BL/6 mice after BDA-410 
treatment. This scheme shows several signaling cascades and the 
corresponding metabolic pathways involved in skeletal muscle-adipose 
tissue crosstalk. The plus (+) and minus (−) signs represent upregulated 
and downregulated genes, respectively, in BDA-treated mice compared to 
vehicle-treated mice. Arrows show positive regulation, whereas truncated 
lines represent an inhibitory action or effect. TG  =  triglycerides; NEFA/
LCFA  =  nonesterified fatty acids/long-chain fatty acids; VLD  =  very-low-
density lipoprotein. Figure  6. PPP1R12B protein levels decrease in the skeletal muscle of old 
mice after BDA-410 treatment. (A) Representative PPP1R12B and GAPDH 
immunoblots in gastrocnemius muscles from BDA-410-treated (n  =  5) and 
vehicle-treated (n = 4) groups. (B) PPP1R12B expression levels normalized to 
GAPDH (*p = .024).
1050 Journals of Gerontology: BIOLOGICAL SCIENCES, 2017, Vol. 72, No. 8
D
ow
nloaded from
 https://academ
ic.oup.com
/biom
edgerontology/article-abstract/72/8/1045/2328593 by guest on 04 Septem
ber 2019
binding proteins, especially FABP4. Exposing C2C12 muscle cells 
to PPARβ/δ agonist increases FABP expression and lipid catabolism 
(27). PPARδ increases Acsl3, which facilitates β-oxidation, thermo-
genesis, and antioxidation.
Besides increasing lipolysis, BDA-410 may reduce body fat 
content by inhibiting or blocking adipogenesis and adipocyte dif-
ferentiation. We show here that BDA-410 significantly increased 
the expression of two potential myokines with anti-adipogenic 
properties, Retnla and Ifi27l2a. Retnla codifies for small, cysteine-
rich, secreted proteins termed resistin-like alpha (RETNLA), which 
inhibit adipocyte differentiation (28). They are downregulated 
in a mouse model of obesity (29) and exert an “atheroprotective 
cytokine” effect that lowers cholesterol specifically during hyper-
lipidemia states (30). We speculate that upregulation of Rentla 
levels is an adaptive reaction to increased FFAs in the circulation. 
Increased Ifi27l2a expression might reduce body fat by inhibiting 
adipogenesis. 
BDA-410 and Lean Phenotype-Related Genes
Upregulation of Ppard, Adipoq, Ucp3, and Dgat1 has been directly 
associated with body fat and weight loss (31). Dgat1 codifies for 
diacylglycerol O-acyltransferase 1, an endoplasmic reticulum-based 
enzyme involved in triglyceride and retinol synthesis. Increased 
Dgat1 expression is responsible for the so-called “athletes’ paradox” 
where both FFA oxidation and triglyceride storage increase in skel-
etal muscle (32). Mitochondrial UCP are also involved in fatty acid 
oxidation in skeletal muscle. UCP3 is codified by the Ucp3 gene, 
which is positively regulated by PPARδ (22). It seems to be acti-
vated by FFAs and reactive oxygen species, and even mild overex-
pression of UCP3 in skeletal muscle can increase energy expenditure 
and decrease body weight (31). Here, we report that both genes, 
Dgat1 and Ucp3, are upregulated in skeletal muscle after adminis-
tering BDA-410 to old mice, possibly contributing to the observed 
lean phenotype.
BDA-410 and Oxidative Response
A side effect of increased lipolysis and hyperlipidemia is increased 
reactive oxygen species production in tissues with elevated FFA 
uptake and oxidation. In skeletal muscle, the main species are super-
oxide anion and nitric oxide, which can modulate several cellular 
functions and have deleterious effects (33). As expected, to protect 
the cell during increased reactive oxygen species production, many 
elements of oxidative stress response are activated, including super-
oxide dismutase (SOD), peroxiredoxin (PRDX), and glutathione 
peroxidase (GPX). As BDA-410 upregulated the Sod3, Prdx2, Gpx1, 
and Gpx3 genes, we hypothesize that the protective response to 
reactive oxygen species could be triggered by an increased supply of 
FFAs to the skeletal muscle.
Myosin Phosphorylation and Muscle Contraction Force
BDA-410 successfully attenuated pathologic phenotypes in several 
mouse models of disease, including models of Alzheimer’s disease, 
aortic aneurism, sickle-cell disease, malaria, spinocerebellar ataxia 
type 3, and an α-klotho knockout mouse model of premature and 
accelerated aging (15,34–38). However, the effects of BDA-410 in 
aging mouse skeletal muscle have only recently been explored (10).
We demonstrated that oral administration of BDA-410 to aging 
C57BL/6 mice inhibited calpain activity in the skeletal muscle and 
enhanced contraction force in soleus muscle with no change in mus-
cle mass or fiber type composition. This improvement in muscle 
performance is related to Cav1.1 upregulation, as TnT3 fragmenta-
tion decreases along with CT-TnT3 repression of the Cacna1s pro-
moter (10). Here, we found that BDA-410 downregulated PPP1R12B, 
a key positive regulatory subunit of the myosin phosphatase 1 cata-
lytic subunit delta, which is highly expressed in skeletal muscle (39). 
It enhances myosin dephosphorylation and reduces calcium sensi-
tivity to promote myofilament relaxation (40). Although PPP1R12B 
has not yet been reported as a calpain substrate, its leucine-enriched 
region can be targeted and cleaved by calpains (41). Therefore, we 
hypothesized that reduced PPP1R12B levels might increase the half-
life of phosphorylated myosin and muscle contraction force, consist-
ent with our previous data showing improved muscle performance 
after BDA-410 administration (10). Our proteomics data agree with 
our prior observation that BDA-410 does not modify overall skeletal 
muscle protein expression (10).
Muscle Force Determinants and Energy Metabolism
Evidence of a link between excitation–contraction coupling and 
energy metabolism in murine skeletal muscle was recently reported 
(42). The Cav1.1 channel can modulate fatty acid uptake and oxida-
tion in the myofiber through calcium influx, CaMKII activation, and 
NO formation. Mice with a genetically modified Cav1.1 α1 subunit 
that blocks calcium permeation gained more body weight and fat 
mass on a chow diet than control mice, without changes in food 
intake or activity, suggesting that Cav1.1-mediated CaMKII activa-
tion affects muscle energy expenditure. Considering our previous 
report on muscle force improvement and the restoration of Cav1.1 
level in old, sedentary mice after BDA-410 administration (10), and 
that Cav1.1 also plays a role in excitation-transcription coupling 
(43,44), we believe that further studies should determine the link 
between these phenomena and the differential expression of the key 
lipid metabolism-related genes reported here.
Limitations
We recognize several limitations to our study. First, the proteins 
encoded by the significantly modified transcripts are not represented 
in our proteomics analysis, and we do not know whether they change 
with BDA-410 treatment. Second, our data cannot define whether 
BDA-410’s role in lipid metabolism depends on its recognized role 
as a calpain inhibitor. Third, despite our robust evidence that BDA-
410 administration in aged mice leads to differential gene expres-
sion, our results do not clearly identify the event that triggers these 
changes, probably due to the broad, only partially understood tar-
gets of calpain in skeletal muscle. Fourth, because the calpain inhibi-
tor is administered systemically, changes induced in tissues, such 
as WAT or pancreas, might influence the skeletal muscle response. 
Fifth, we do not know whether BDA-410 affects macronutrient 
excretion in feces; however, this has not been reported in previous 
studies of the effects of BDA-410 on various disease conditions and 
aging (10,15,34–38,45). Sixth, we cannot say whether the effects of 
BDA-410 reported here are sex specific; future studies should include 
male mice. Finally, future studies should determine whether more 
prolonged administration or a higher BDA-410 concentration pro-
duces stronger effects.
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